Federal contract award
W911SR22F0014
CLINICAL DEVELOPMENT PHASE 2 STUDY
Award details
Obligations, current value and potential value describe different measures; they are never added together.
| Field | Reported value |
|---|---|
| Agency | Department of Defense |
| Office | W6QK ACC-APG |
| NAICS | 541715 — Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) |
| PSC | AN42 — HEALTH R&D SERVICES; HEALTH CARE - OTHER; APPLIED RESEARCH |
| Parent award / vehicle | W911SR22D0009 |
| Set-aside | Not reported |
| Pricing type | COST PLUS FIXED FEE |
| Obligations | $93.0M |
| Current contract value | $107.9M |
| Potential contract value / ceiling | $107.9M |
| Start date | Jan 4, 2022 |
| Current end date | Dec 30, 2025 |
| Potential end date | Dec 30, 2025 |
| Latest award activity | Dec 30, 2025 |
| Source loaded | Sep 19, 2026 |
Funding and modification history
Showing the latest 8 of 8 loaded transactions. Negative values are deobligations.
| Date | Modification | Obligation change | Description |
|---|---|---|---|
| Dec 30, 2025 | P00027 | $0 | THIS DELIVERY ORDER IS FOR TASKS ASSOCIATED WITH THE DEVELOPMENT OF US FOOD AND DRUG ADMINISTRATION LICENSED MONOCLONAL ANTIBODY COUNTERMEASURE FOR BOTULINUM NEUROTOXIN EXPOSURE. |
| Sep 23, 2025 | P00025 | $1.6M | THIS DELIVERY ORDER IS FOR TASKS ASSOCIATED WITH THE DEVELOPMENT OF US FOOD AND DRUG ADMINISTRATION LICENSED MONOCLONAL ANTIBODY COUNTERMEASURE FOR BOTULINUM NEUROTOXIN EXPOSURE. |
| Sep 23, 2025 | P00026 | $-3.1M | THIS DELIVERY ORDER IS FOR TASKS ASSOCIATED WITH THE DEVELOPMENT OF US FOOD AND DRUG ADMINISTRATION LICENSED MONOCLONAL ANTIBODY COUNTERMEASURE FOR BOTULINUM NEUROTOXIN EXPOSURE. |
| Sep 22, 2025 | P00022 | $-6.6M | THIS DELIVERY ORDER IS FOR TASKS ASSOCIATED WITH THE DEVELOPMENT OF US FOOD AND DRUG ADMINISTRATION LICENSED MONOCLONAL ANTIBODY COUNTERMEASURE FOR BOTULINUM NEUROTOXIN EXPOSURE. |
| Sep 22, 2025 | P00023 | $-4.5M | THIS DELIVERY ORDER IS FOR TASKS ASSOCIATED WITH THE DEVELOPMENT OF US FOOD AND DRUG ADMINISTRATION LICENSED MONOCLONAL ANTIBODY COUNTERMEASURE FOR BOTULINUM NEUROTOXIN EXPOSURE. |
| Sep 22, 2025 | P00024 | $-2.3M | THIS DELIVERY ORDER IS FOR TASKS ASSOCIATED WITH THE DEVELOPMENT OF US FOOD AND DRUG ADMINISTRATION LICENSED MONOCLONAL ANTIBODY COUNTERMEASURE FOR BOTULINUM NEUROTOXIN EXPOSURE. |
| Apr 14, 2025 | P00021 | $0 | THIS DELIVERY ORDER IS FOR TASKS ASSOCIATED WITH THE DEVELOPMENT OF US FOOD AND DRUG ADMINISTRATION LICENSED MONOCLONAL ANTIBODY COUNTERMEASURE FOR BOTULINUM NEUROTOXIN EXPOSURE. |
| Feb 18, 2025 | P00020 | $0 | THIS DELIVERY ORDER IS FOR TASKS ASSOCIATED WITH THE DEVELOPMENT OF US FOOD AND DRUG ADMINISTRATION LICENSED MONOCLONAL ANTIBODY COUNTERMEASURE FOR BOTULINUM NEUROTOXIN EXPOSURE. |
Research next steps
- Confirm the ordering vehicle and your eligibility or a qualified teaming route.
- Review the award scope and buyer evidence before making a bid/no-bid decision.